Action RV6 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Charles River Laboratories International, Inc. BOERSE MUENCHEN

Actions

RV6

US1598641074

Marché Fermé - BOERSE MUENCHEN
Autres places de cotation
 21:43:00 26/06/2024 		Varia. 5j. Varia. 1 janv.
192,8 EUR +0,81% Graphique intraday de Charles River Laboratories International, Inc. -0,67% -10,09%
25/06 Charles River Laboratories et l'Institut Gates collaborent à la fabrication de vecteurs lentiviraux MT
25/06 Charles River Laboratories annonce une collaboration stratégique pour la fabrication de vecteurs lentiviraux avec le Gates Institute de l'Université du Colorado Anschutz Medical Campus CI

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute at University of Colorado Anschutz Medical Campus
BU
Charles River and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy
BU
Charles River Laboratories, in Collaboration With MatTek Corporation, Awarded Grant from the Foundation for Chemistry Research and Initiatives to Advance Research Alternatives
BU
Charles River Laboratories Expands Access to CRADL Contract Vivarium Space in Somerville
AQ
Charles River Laboratories Expands Access to CRADL® Contract Vivarium Space in Somerville
BU
Charles River Laboratories Announces Development of Nonclinical Virtual Control Groups with Sanofi to Reduce the Use of Animals in Research
BU
Charles River Laboratories to Present at William Blair and Jefferies Conferences
BU
Charles River Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development
BU
Charles River: Q1 Earnings Snapshot
AQ
Charles River Laboratories Announces First-Quarter 2024 Results
BU
Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP
BU
Charles River Laboratories International : Proxy Supplement Filed April 24, 2024
PU
Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
BU
Charles River Laboratories International : 2023 Corporate Citizenship Report
PU
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing
BU
Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call
AQ
Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call
BU
Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology
BU
Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics
BU
Charles River to Perform Plasmid Production for Ship of Theseus
BU
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action CRL
  4. Action RV6
  5. Actualités Charles River Laboratories International, Inc.
  6. Communiqués